This content is machine translated Heart failure in the light of the latest evidence MRAs offer advantages across the entire EF spectrum At the swissESCupdate, cardiology experts summarized important content from this year’s Annual Meeting of the European Society of Cardiology . In the area of heart failure, studies on the use…
View Post 8 min This content is machine translated Heart failure: ESC guideline update 2023 Therapy-relevant new evidence on the entire EF spectrum The update of the ESC guideline on the treatment of heart failure includedthe results of large randomized studies that were not published until after the guideline was published in 2021.…
View Post 4 min This content is machine translated ESC guidelines on heart failure These are the new recommendations Numerous studies published in the last two years made it necessary to update the 2021 ESC Heart Failure Guidelines. In particular, this refers to new studies on SGLT2 inhibitors in…
View Post 4 min This content is machine translated Heart failure: ESC guideline update 2023 Treatment of HFmrEF – what’s new? The European Society of Cardiology (ESC) recently updated its guidelines. Consequently, based on the EMPEROR-Preserved and DELIVER trials, the use of SGLT-2 inhibitors is now recommended for all stages of…
View Post 5 min This content is machine translated Heart failure in type 2 diabetes Success story of SGLT-2 inhibitors – impressive evidence base. The SGLT(“sodium glucose-linked transporter”)-2 inhibitors have demonstrated cardioprotective effects in addition to antidiabetic effects. The current evidence supports the benefit of several agents of SGLT-2-i in the treatment of heart…
View Post 5 min This content is machine translated Heart failure Pharmacotherapy in HFrEF and HFmrEF – Combination of four as gold standard. Important therapeutic goals in chronic heart failure are to improve quality of life and to reduce the risk of hospitalization and mortality. According to current evidence, guideline-based therapy with the…
View Post 6 min This content is machine translated Heart failure Dapagliflozin now approved in preserved ejection fraction [1,4]** After dapagliflozin had been approved for some time for heart failure with reduced ejection fraction, Swissmedic now granted an indication extension for heart failure with mildly reduced or preserved ejection…
View Post 6 min This content is machine translated Suspected heart failure - what to do? Expert recommendations up-to-date According to the European Society of Cardiology (ESC) guideline updated last year, heart failure is classified into HFrEF, HFmrEF, and HFpEF according to left ventricular ejection fraction. Regarding drug therapy, early…
View Post 4 min This content is machine translated Heart Failure Congress of the ESC, Paris “Mid-range heart failure” – what does it mean in practice? Systolic or diastolic heart failure? In 10-20% of heart failure patients, the answer to this question is: neither. You have heart failure with an ejection fraction in the “mid-range,” that…
